SOX2 expression is an early event in a murine model of EGFR mutant lung cancer and promotes proliferation of a subset of EGFR mutant lung adenocarcinoma cell lines

Creative Commons License

Dogan I., Kawabata S., Bergbower E., Gills J. J., Ekmekci A., Wilson W., ...Daha Fazla

LUNG CANCER, cilt.85, sa.1, ss.1-6, 2014 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 85 Sayı: 1
  • Basım Tarihi: 2014
  • Doi Numarası: 10.1016/j.lungcan.2014.03.021
  • Dergi Adı: LUNG CANCER
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1-6
  • Anahtar Kelimeler: SOX2, Non-small cell lung cancer, EGFR, Akt, Erlotinib, H1975, HCC827, STEM-LIKE CELLS, SELF-RENEWAL, TUMOR, IDENTIFICATION, GEFITINIB, SENSITIVITY, RESISTANCE, MUTATIONS, CARCINOMA, ONCOGENE
  • Gazi Üniversitesi Adresli: Evet

Özet

Objectives: Primary and acquired resistance to EGFR TKIs in EGFR mutant lung cancer occurs primarily through secondary mutations in EGFR or Met amplification. Drug resistance can also be mediated by expression of pluripotency transcription factors, such as OCT4, SOX2 and NANOG that decrease terminal differentiation. In this study, we investigated the expression and role of SOX2 in model systems of EGFR mutant tumors.